Educational Objectives

 Recognize the role of rosuvastatin and other approved statins
 in the management of dyslipidemias.

 Understand the comparative pharmacokinetics of rosuvastatin
 and other approved statins.

 Assess global CHD risk factors and genetic disorders.

 Understand the role of inflammatory markers in CHD risk.

Subject Content

 Safety, efficacy and pharmacokinetics of rosuvastatin.

 Mechanism of action of emerging therapy for dyslipidemias.

 Role of inflammatory markers in dyslipidemias.

 Global risk assessment.

 Genetic disorders.

This edition is for information and study purposes only as the
CME credits have expired.

Back to Complex Lipid Management